Dr John W Stevens

All publications

Journal articles

• Johnston PI, Wright SW, Orr M, Pearce FA, Stevens JW, Hubbard RB & Collini PJ (2021) Worldwide relative smoking prevalence among people living with and without HIV : a systematic review and meta-analysis. AIDS. View this article in WRRO
• Hulin J, Brodie A, Stevens J & Mitchell C (2020) Prevalence of respiratory conditions among people who use illicit opioids: a systematic review. Addiction, 115(5), 832-849. View this article in WRRO
• Horner D, Stevens JW, Pandor A, Nokes T, Keenan J, Wit K & Goodacre S (2020) Reply to Thromboprophylaxis in temporary lower limb immobilization : extrapolate with care. Journal of Thrombosis and Haemostasis, 18(2), 519-520. View this article in WRRO
• Horner D, Stevens JW, Pandor A, Nokes T, Keenan J, de Wit K & Goodacre S (2020) Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury : systematic review and network meta‐analysis. Journal of Thrombosis and Haemostasis, 18(2), 422-438. View this article in WRRO
• Kearns B, Stevens J, Ren S & Brennan A (2020) How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. PharmacoEconomics, 38(2), 193-204. View this article in WRRO
• Pandor A, Horner D, Davis S, Goodacre S, Stevens JW, Clowes M, Hunt BJ, Nokes T, Keenan J & de Wit K (2019) Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment, 23(63), 1-190. View this article in WRRO
• Bell Gorrod H, Kearns B, Stevens J, Thokala P, Labeit A, Latimer N, Tyas D & Sowdani A (2019) A review of survival analysis methods used in NICE technology appraisals of cancer treatments: Consistency, limitations and areas for improvement. Medical Decision Making. View this article in WRRO
• Horner D, Goodacre S, Pandor A, Nokes T, Keenan J, Hunt B, Davis S, Stevens JW & Hogg K (2019) Thromboprophylaxis in lower limb immobilisation after injury (TiLLI). Emergency Medicine Journal, 0, 1-6. View this article in WRRO
• Kapetanakis V, Prawitz T, Schlichting M, Ishak KJ, Phatak H, Kearney M, Stevens JW, Benedict A & Bharmal M (2019) Assessment-schedule matching in unanchored indirect treatment comparisons of progression-free survival in cancer studies. PharmacoEconomics. View this article in WRRO
• Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 23(30). View this article in WRRO
• Davis S, Goodacre S, Pandor A, Horner D, Stevens JW, Wit K & Hunt BJ (2019) Decision‐analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. British Journal of Haematology, 186(1), 166-168. View this article in WRRO
• Squires H, Bermejo I, Poku EN, Cooper K, Stevens J, Hamilton J, Wong R, Denniston AK, Pearce I & Quhill FM (2019) Dexamethasone implant for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology. View this article in WRRO
• Bermejo I, Squires H, Poku EN, Cooper K, Stevens JW, Hamilton J, Wong R, Pearce I, Quhill FM & Denniston AK (2019) Adalimumab for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology. View this article in WRRO
• Simpson EL, Ren S, Hock ES, Stevens JW, Binard A, Pers Y-M, Archer R, Paisley S, Stevenson MD, Herpin C & Ghabri S (2019) Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.. International Journal of Technology Assessment in Health Care. View this article in WRRO
• Tappenden P, Carroll C, Stevens J, Simpson E, Thokala P, Wong R, Wright J & Auer R (2019) Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 37(1), 7-18. View this article in WRRO
• Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, Clowes M, Pandor A & Stevenson M (2018) Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.. Health Technology Assessment, 22(66), 1-294. View this article in WRRO
• Stevens JW (2018) Using evidence from randomised controlled trials in economic models: What information is relevant and is there a minimum amount of sample data required to make decisions?. PharmacoEconomics. View this article in WRRO
• Ren S, Oakley JE & Stevens JW (2018) Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses. Medical Decision Making, 38(4), 531-542. View this article in WRRO
• Rafia R, Pandor A, Davis S, Stevens JW, Harnan S, Clowes M, Sorour Y & Cutting R (2018) Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1143-1151. View this article in WRRO
• Grimm SE, Dixon S & Stevens JW (2018) Estimating future health technology diffusion using expert beliefs to inform an established diffusion model. Value in Health. View this article in WRRO
• Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A & Wong R (2018) Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(7), 759-768. View this article in WRRO
• Pandor A, Stevenson M, Stevens J, James MM-S, Hamilton J, Byrne J, Rudin C, Rawdin A & Wong R (2018) Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(8), 903-915. View this article in WRRO
• Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R & Wyld L (2018) Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics, 36(1), 29-38. View this article in WRRO
• Stevens JW, Fletcher C, Downey G & Sutton A (2017) A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence. Research Synthesis Methods. View this article in WRRO
• Squires HY, Poku E, Bermejo I, Cooper K, Stevens J, Hamilton J, Wong R, Denniston A, Pearce I & Quhill F (2017) A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate, posterior or panuveitis in adults. Health technology assessment, 21(68). View this article in WRRO
• Bermejo I, Stevenson M, Archer R, Stevens JW, Goka E, Clowes M, Scott DL & Young A (2017) Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(11), 1141-1151. View this article in WRRO
• Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F & Ghazavi M (2017) Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(8), 805-815. View this article in WRRO
• Grimm SE, Dixon S & Stevens JW (2017) Assessing the Expected Value of Research Studies in Reducing Uncertainty and Improving Implementation Dynamics. Medical Decision Making, 37(5), 523-533. View this article in WRRO
• Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A & Scott DL (2017) The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. Journal of Rheumatology, 44(7), 973-980. View this article in WRRO
• Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A & Sharples L (2017) Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making, 37(4), 377-390. View this article in WRRO
• Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D , Young A et al (2016) Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 611-614.
• Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 1-406. View this article in WRRO
• Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. PharmacoEconomics, 34(10), 1023-1038. View this article in WRRO
• Grimm SE, Dixon S & Stevens JW (2016) When future change matters: modelling future price and diffusion in health technology assessments of medical devices. Value in Health, 19(6), 720-726. View this article in WRRO
• Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M & Lobo A (2016) Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(12), 1241-1253. View this article in WRRO
• Sanderson J, Martyn-St James M, Stevens J, Goka E, Wong R, Campbell F, Selby P, Gittoes N & Davis S (2016) Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. Bone, 89, 52-58. View this article in WRRO
• Thokala P, Simpson E, Tappenden P, Stevens J, Dickinson K, Ryder S & Harrison P (2016) Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective. PharmacoEconomics, 34(8), 741-750. View this article in WRRO
• Squires H, Stevenson M, Simpson E, Harvey R & Stevens J (2016) Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(7), 673-680. View this article in WRRO
• Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, Sanderson J, Wong R, Perkins GD, McMullan R & Dark P (2016) Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.. Health Technology Assessment, 20(46), 1-246. View this article in WRRO
• Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A & Hoque S (2016) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment, 20(39), 1-326. View this article in WRRO
• Morrell CJ, Sutcliffe P, Booth A, Stevens J, Scope A, Stevenson M, Harvey R, Bessey A, Cantrell A, Dennis C-L , Ren S et al (2016) A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. Health Technology Assessment, 20(37), 1-414. View this article in WRRO
• Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D , Young A et al (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 1-610. View this article in WRRO
• Gray EP, Teare MD, Stevens J & Archer R (2016) Risk Prediction Models for Lung Cancer: A Systematic Review. Clinical Lung Cancer, 17(2), 95-106.
• Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J & Morgan MY (2015) Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 33(8), 833-847. View this article in WRRO
• Stevens JW, Khunti K, Harvey R, Johnson M, Preston L, Woods HB, Davies M & Goyder E (2015) Preventing the progression to Type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice, 107(3), 320-331.
• Goodacre S, Stevens JW, Pandor A, Poku E, Ren S, Cantrell A, Bounes V, Mas A, Payen D, Petrie D , Roessler MS et al (2014) Prehospital Noninvasive Ventilation for Acute Respiratory Failure: Systematic Review, Network Meta-analysis, and Individual Patient Data Meta-analysis. Academic Emergency Medicine, 21(9), 960-970. View this article in WRRO
• Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Cantrell A & Michaels J (2014) Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins.. Br J Surg, 101(9), 1040-1052. View this article in WRRO
• Leaviss J, Hummel S, Carroll C, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M & Michaels J (2014) Clinical and cost-effectiveness of minimally invasive techniques for the treatment of varicosis: Systematic review and economic evaluation. Vasomed, 26(4), 210-211.
• Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, Michaels J, Stansby G & O'Donnell ME (2014) Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.. Angiology, 65(3), 190-197.
• Goodacre S, Cohen J, Bradburn M, Stevens J, Gray A, Benger J, Coats T & 3Mg Research Team (2014) The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma.. Health Technol Assess, 18(22), 1-168.
• Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, Strong M & Cantrell A (2014) What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.. Health Technol Assess, 18(33), 1-120.
• Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, Archer R, Evans P & Wang J (2014) Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation.. Health Technol Assess, 18(16), 1-176.
• Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J & Stansby G (2013) Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).. Br J Surg, 100(13), 1838-1839.
• Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M & Michaels J (2013) Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation.. Health Technol Assess, 17(48), i-141.
• Pandor A, Thokala P, Gomersall T, Baalbaki H, Stevens JW, Wang J, Wong R, Brennan A & Fitzgerald P (2013) Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation.. Health Technol Assess, 17(32), 1-vi. View this article in WRRO
• Pandor A, Gomersall T, Stevens JW, Wang J, Al-Mohammad A, Bakhai A, Cleland JGF, Cowie MR & Wong R (2013) Remote monitoring after recent hospital discharge in patients with heart failure: A systematic review and network meta-analysis. Heart, 99(23), 1717-1726.
• Tosh J, Archer R, Davis S, Stevenson M & Stevens JW (2013) Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.. Pharmacoeconomics, 31(8), 653-661.
• Thokala P, Baalbaki H, Brennan A, Pandor A, Stevens JW, Gomersall T, Wang J, Bakhai A, Al-Mohammad A, Cleland J , Cowie MR et al (2013) Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs.. BMJ Open, 3(9), e003250. View this article in WRRO
• Goodacre S, Thokala P, Carroll C, Stevens JW, Leaviss J, Al Khalaf M, Collinson P, Morris F, Evans P & Wang J (2013) Systematic review, meta-analysis and economic modelling of diagnostic strategies for suspected acute coronary syndrome.. Health Technol Assess, 17(1), v-188.
• Carroll C, Khalaf MA, Stevens JW, Leaviss J, Goodacre S, Wang J & Collinson PO (2013) Heart-type fatty acid binding protein as an early marker for myocardial infarction: Systematic review and meta-analysis. Emergency Medicine Journal, 30(4), 280-286.
• Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J & Stansby G (2012) Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.. Br J Surg, 99(12), 1630-1638.
• Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H & Stevens J (2012) Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.. Health Technol Assess, 16(37), 1-iv.
• Thokala P, Goodacre SW, Collinson PO, Stevens JW, Mills NL, Newby DE, Morris F, Kendall J & Stevenson MD (2012) Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. Heart, 98(20), 1498-1503.
• Turner RM, Lloyd-Jones M, Anumba DOC, Smith GCS, Spiegelhalter DJ, Squires H, Stevens JW, Sweeting MJ, Urbaniak SJ, Webster R & Thompson SG (2012) Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality.. PLoS One, 7(2), e30711. View this article in WRRO
• Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS & Stevenson M (2012) Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. Eur J Prev Cardiol, 19(3), 474-483.
• Hutchinson K & Stevens JW (2011) Pharmaceutical Statistics 10th anniversary. Pharmaceutical Statistics, 10(6), 475-476.
• Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J & Stansby G (2011) A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.. Health Technol Assess, 15(40), 1-210.
• Papaioannou D, Rafia R, Stevenson MD, Stevens JW & Evans P (2011) Trabectedin for the treatment of relapsed ovarian cancer.. Health technology assessment (Winchester, England), 15 Suppl 1, 69-75.
• Stevens JW (2011) A note on dealing with missing standard errors in meta-analyses of continuous outcome measures in WinBUGS.. Pharm Stat, 10(4), 374-378.
• Stevens JW (2011) Uncertainty analysis is inherently Bayesian.. Value Health, 14(1), 202-203.
• Stevens JW (2010) NICE work: how NICE decides what we should pay for. BRIT J GEN PRACT, 60(570), 7-8.
• Nixon RM, O'Hagan A, Oakley J, Madan J, Stevens JW, Bansback N & Brennan A (2009) The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. PHARM STAT, 8(4), 371-389. View this article in WRRO
• Nixon RM, Bansback N, Stevens JW, Brennan A & Madan J (2009) Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. PHARM STAT, 8(2), 150-162.
• Ara R, Pandor A, Stevens J, Rees A & Rafia R (2009) Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(34).
• Zhou Y, Whitehead J, Bonvini E & Stevens JW (2006) Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. Pharmaceutical Statistics, 5(2), 125-133.
• Whitehead J, Zhou Y, Stevens J, Blakey G, Price J & Leadbetter J (2005) Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Statistics in medicine, 25(1), 37-53.
• O'Hagan A, Stevens JW & Campbell MJ (2005) Assurance in clinical trial design. PHARM STAT, 4(3), 187-201.
• O'Hagan A & Stevens JW (2004) On estimators of medical costs with censored data.. J Health Econ, 23(3), 615-625.
• Whitehead J, Zhou Y, Stevens J & Blakey G (2004) An Evaluation of a Bayesian Method of Dose Escalation Based on Bivariate Binary Responses. Journal of Biopharmaceutical Statistics, 14(4), 969-983.
• Stevens JW, O'Hagan A & Miller P (2003) Case study in the Bayesian analysis of a cost-effectiveness trial in the evaluation of health care technologies: Depression. PHARM STAT, 2(1), 51-68.
• O'Hagan A & Stevens JW (2003) Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?. Health Econ, 12(1), 33-49.
• Stevens JW & O'Hagan A (2002) Incorporation of genuine prior information in cost-effectiveness analysis of clinical trial data.. Int J Technol Assess Health Care, 18(4), 782-790. View this article in WRRO
• O'Hagan A & Stevens JW (2002) Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.. Stat Methods Med Res, 11(6), 469-490.
• Lindsey JK, Stevens JW, Jones B & Jackson D (2002) Dynamic modelling of a challenge-escalation cross-over study of treatment of capsaicin-induced coughing. Statistics in medicine, 21(20), 3023-3033.
• Whitehead J, Stevens J, Brodie M, Wroe S, Dean A & Holdich T (2002) Remacemide versus carbamazepine in newly diagnosed epilepsy. Epilepsy & Behavior, 3(4), 405-405.
• Brodie MJ, Wroe SJ, Dean ADP, Holdich TAH, Whitehead J & Stevens JW (2002) Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. Epilepsy & Behavior, 3(2), 140-146.
• O'Hagan A & Stevens JW (2002) The probability of cost-effectiveness.. BMC Med Res Methodol, 2, 5.
• O'Hagan A & Stevens JW (2001) A framework for cost-effectiveness analysis from clinical trial data.. Health Econ, 10(4), 303-315.
• O'Hagan A & Stevens JW (2001) Bayesian assessment of sample size for clinical trials of cost-effectiveness.. Med Decis Making, 21(3), 219-230.
• O'Hagan A, Stevens JW & Montmartin J (2001) Bayesian cost-effectiveness analysis from clinical trial data.. Stat Med, 20(5), 733-753.
• O'Hagan A, Stevens JW & Montmartin J (2000) Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.. Pharmacoeconomics, 17(4), 339-349.
• Fernández-Cruz E, Lang J, Frissen PHJ, Furrier V, Châateauvert M, Boucher CAB, Dowd P & Stevens J (1995) Zidovudine plus interferon-[alpha] versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts> 150x106/l: results of the Zidon trial. Aids, 9(9), 1025-1036.
• Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel F, Bruun JN, Stingl G, Melville RL & Gonzalez-Lahoz J (1993) Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. New England Journal of Medicine, 329(5), 297-303.
• Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al () Corrigendum: A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 407-424. View this article in WRRO
• Papaioannou D, Rafia R, Stevenson MD, Stevens JW & Evans P () Trabectedin for the treatment of relapsed ovarian cancer. Health Technology Assessment, 15(Suppl 1), 69-75.
• Pandor A, Thokala P, Goodacre S, Poku E, Stevens JW, Ren S, Cantrell A, Perkins GD, Ward M & Penn-Ashman J () Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technology Assessment, 19(42), 1-102. View this article in WRRO
• Uttley L, Scope A, Stevenson M, Rawdin A, Taylor Buck E, Sutton A, Stevens J, Kaltenthaler E, Dent-Brown K & Wood C () Systematic review and economic modelling of the clinical effectiveness and cost-effectiveness of art therapy among people with non-psychotic mental health disorders. Health Technology Assessment, 19(18), 1-120. View this article in WRRO

Conference proceedings papers

• Kapetanakis V, Schlichting M, Stevens JW, Prawitz T, Kearney M, Phatak H, Benedict A & Bharmal M (2018) Assessment-Time Bias: Statistical Approaches to Adjusting for Between-Trial Differences in the Schedule of Assessment for Disease Progression In Immuno-Oncology Trials. Value in Health, Vol. 21 (pp S10-S10)
• Ren S, Oakley JE & Stevens JW (2017) EVIDENCE SYNTHESIS FOR HEALTH TECHNOLOGY ASSESSMENT WITH LIMITED STUDIES. VALUE IN HEALTH, Vol. 20(9) (pp A770-A770)
• Morrell J, Sutcliffe P, Stevenson M, Stevens J, Booth A, Scope A, Bessey A, Dennis C-L, Cantrell A, Barkham M , Churchill D et al (2015) Prevention of postnatal depression: a meta-analysis of interventions to prevent postnatal depression. Journal of Reproductive and Infant Psychology, Vol. 33(3) (pp E3-E4), 13 September 2016 - 14 September 2016. View this article in WRRO
• Pandor A, Gomersall T, Stevens JW & Wong R (2015) Remote monitoring strategies for patients with stable Heart failure: a systematic review and Network meta-analysis. Value in Health, Vol. 18(3) (pp A248-A248)
• Wailoo AJ, Stevenson M, Tosh J, Hernández M, Stevens JW, Archer R, Simpson E, everson HE, Scott D, Young A , Paisley S et al (2014) The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards. Value in Health, Vol. 17(7) (pp A380-A380)
• Almond C, Stevens JW, Ren K & Batty A (2013) THE ESTIMATED SURVIVAL OF PATIENTS WITH DOUBLE REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA; A REANALYSIS OF NICE TA202 USING BAYESIAN METHODOLOGY TO MODEL OBSERVED DATA. VALUE IN HEALTH, Vol. 16(7) (pp A397-A397)
• Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, Michaels J, Stansby G & O'Donnell M (2012) COST-EFFECTIVENESS OF CILOSTAZOL, NAFTIDROFURYL OXALATE, PENTOXIFYLLINE AND INOSITOL NICOTINATE FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN PEOPLE WITH PERIPHERAL ARTERIAL DISEASE IN THE UK. VALUE IN HEALTH, Vol. 15(7) (pp A633-A633)
• Carroll C, Goodacre S, Stevens J, Al Khalaf M, Leaviss J, Wang J & Collinson P (2012) DIAGNOSTIC ACCURACY OF EARLY BIOMARKERS FOR ACUTE CORONARY SYNDROME (ACS). VALUE IN HEALTH, Vol. 15(7) (pp A361-A361)
• Brennan A, Thokala P, Baalbaki H, Stevens JW, Wang J & Pandor A (2012) TELEMONITORING AFTER DISCHARGE WITH HEART FAILURE - COST-EFFECTIVENESS MODELLING OF ALTERNATIVE SERVICE DESIGNS. VALUE IN HEALTH, Vol. 15(7) (pp A360-A360)
• Thokala P & Goodacre SW (2012) PMD40 Cost-Effectiveness of Presentation and Delayed Troponin Testing for Acute Myocardial Infarction. Value in Health, Vol. 15(4) (pp A69-A69)
• Van Hout BA & Stevens JW (2011) THE POWER OF ASSUMPTIONS. VALUE IN HEALTH, Vol. 14(7) (pp A235-A235)
• Stevens J, Keith MS & Hodgkins P (2009) USE OF A BAYESIAN MIXED TREATMENT META ANALYSIS TO SUPPORT REIMBURSEMENT DECISION MAKING OF PHOSPHATE BINDER THERAPY IN END-STAGE RENAL DISEASE. VALUE IN HEALTH, Vol. 12(7) (pp A308-A308)
• Thokala P, Hassan B, Abdullah P, Stevens JW & Alan B () Cost-effectiveness modelling of telemonitoring after discharge from hospital with heart failure. International Journal of Integrated Care, Vol. 13(7)

Posters

• Bhrmal M, Kapetanakis V, Schlichting M, Stevens JW, Kearnmey M, Phatak H & Benedict A (2018) How to correct for differences in study design when making indirect comparisons using evidence from single-arm studies in immune-oncology.. Academy of Managed Care Pharmacy NEXUS 2018.
• Ghabri S, Simpson EL, Ren S, Hock E, Archer R, Binard A, Pers Y, Stevens JW, Herpin C & Stevenson M (2018) PMS4 - RHEUMATOID ARTHRITIS TREATED WITH SIX-MONTHS OF FIRST-LINE BIOLOGIC OR BIOSIMILAR THERAPY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.
• Archer R, Clowes M, Hamilton J, Pandor A, Stevenson MD, Stevens JW, Hock ES & Essat M (2018) Addressing challenges in the conduct of a systematic review of clinical prediction models in rheumatoid arthritis. 25th Cochrane Colloquium, Edingurgh.
• Hamilton J, Archer R, Stevens J, Stevenson M, Hock E, Clowes M, Essat M, Poku E & Pandor A (2018) Clinical prediction models for patients with early rheumatoid arthritis: A systematic review and evidence synthesis. MEMTAM (Methods for Evaluation of medical prediction Models, Test And Biomarkers), Utecht, The Nethe.
• Ren S, Oakley J & Stevens JW (2018) Evidence synthesis with limited studies. HTAi 2018, Vancouver, Canada.
• Ren S, Oakley J & Stevens JW (2017) Evidence synthesis for health technology assessment with limited studies.. . ISPOR Glasgow 2017.
• Ren S, Oakley JE & Stevens JW (2017) EVidence Synthesis For Health Technology Assessment With Limited Studies.
• Stevens JW, Harvey RC, Johnson M & Khunti K (2014) Preventing the Progression to Type 2 Diabetes Mellitus in Adults at High Risk: A Systematic Review And Network Meta-Analysis of Lifestyle, Pharmacological and Surgical Interventions.
• Goodacre S (2014) PRE-HOSPITAL NON-INVASIVE VENTILATION FOR ACUTE RESPIRATORY FAILURE: A SYSTEMATIC REVIEW AND NETWORK META ANALYSIS.
• Goodacre S, Pandor A, Poku E, Stevens JW, Ren S & Cantrell A Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and network meta-analysis. 999 EMS Research Forum Conference.